Scinai Immunotherapeutics (SCNI) has released an update.
Scinai Immunotherapeutics Ltd. has struck a significant deal, granting exclusive global rights to their patented immunotherapy technologies and related know-how to an unnamed U.S. company. The agreement includes an immediate license fee, contingent milestone payments, and royalties on future net sales. This move marks a strategic step for Scinai in the development and commercialization of its licensed products.
For further insights into SCNI stock, check out TipRanks’ Stock Analysis page.
